Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NYSE American - Nasdaq Real Time Price USD

Matinas BioPharma Holdings, Inc. (MTNB)

Compare
0.5400
+0.0273
+(5.32%)
At close: April 11 at 3:59:51 PM EDT
0.5200
-0.02
(-3.70%)
After hours: April 11 at 5:05:43 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MTNB

Recent News: MTNB

View More
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
GlobeNewswire last month
Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors
GlobeNewswire last month
Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair

Matinas BioPharma Appoints Evelyn D’An to Board of Directors as Audit Committee Chair
GlobeNewswire 2 months ago
Matinas BioPharma Receives NYSE Noncompliance Notice

Matinas BioPharma Receives NYSE Noncompliance Notice
GlobeNewswire 2 months ago
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
GlobeNewswire 5 months ago
Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested

Upcoming Stock Splits This Week (September 2 to September 6) – Stay Invested
TipRanks 7 months ago
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire 7 months ago
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
GlobeNewswire 7 months ago
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
GlobeNewswire 9 months ago
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
GlobeNewswire 9 months ago
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
GlobeNewswire 10 months ago
View More

Related Tickers

EQ Equillium, Inc.
0.4790
+5.04%
 
KANT Kineta, Inc.
0.2660
0.00%
 
PRQR ProQR Therapeutics N.V.
1.1200
-0.88%
 
MTVA MetaVia Inc.
1.4500
+5.07%
 
SLGL Sol-Gel Technologies Ltd.
0.4300
-0.58%
 
CDXS Codexis, Inc.
2.3500
+4.44%
 
MEIP MEI Pharma, Inc.
1.8700
+1.63%
 
ARTL Artelo Biosciences, Inc.
0.8219
-1.33%
 
LIXT Lixte Biotechnology Holdings, Inc.
1.2100
+3.42%
 
NBY NovaBay Pharmaceuticals, Inc.
0.5299
+8.14%